These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19669256)

  • 21. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.
    Sun X; Qin WX; Li YP; Jiang XH
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1369-77. PubMed ID: 17716343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Buti M; Brosa M; Casado MA; Rueda M; Esteban R
    J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
    Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
    Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
    Chen W; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):569-73. PubMed ID: 19719912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
    Han SH
    Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
    Yuan Y; Iloeje U; Li H; Hay J; Yao GB
    Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B.
    Wiens A; Venson R; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2011; 15(3):225-30. PubMed ID: 21670922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
    Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
    Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.